^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin)

    i
    Other names: PTTG1, PTTG1 Regulator Of Sister Chromatid Separation, Securin, Securin, HPTTG, PTTG, EAP1, Tumor-Transforming Protein 1, TUTR1, Pituitary Tumor-Transforming Gene 1 Protein, Pituitary Tumor-Transforming 1, ESP1-Associated Protein 1, Esp1-Associated Protein
    13d
    Identification of unique biomarkers in colorectal cancer based on comprehensive analysis and machine learning. (PubMed, Front Oncol)
    The seven hub RBP genes are potential biomarkers for CRC, providing new insights and therapeutic targets. However, functional validation and larger sample sizes are needed for clinical application.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • DNMT1 (DNA methyltransferase 1) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1) • APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
    18d
    PTTG1 regulates the TGF-β/Smad pathway to promote the growth and metastasis of gastric cancer cells. (PubMed, Hereditas)
    PTTG1 promotes gastric cancer progression by activating the TGF-β/Smad axis to enhance cell proliferation, invasion, and EMT. These findings highlight PTTG1 as a potential diagnostic biomarker and therapeutic target in gastric cancer.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • SMAD3 (SMAD Family Member 3)
    25d
    Integrative Bioinformatics and Experimental Validation Establish CCNB1 as a Potential Biomarker for Diagnosis and Prognosis in Colorectal Cancer. (PubMed, Curr Issues Mol Biol)
    In vitro, CCNB1 knockdown triggered cell cycle arrest, thereby suppressing the proliferation of colorectal cancer cells. This study validated CCNB1 as a dual-purpose biomarker for CRC diagnosis and favorable prognosis, highlighting its potential utility in clinical management.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • CDCA3 (Cell Division Cycle Associated 3) • CCNA2 (Cyclin A2) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • MCM4 (Minichromosome Maintenance Complex Component 4) • CCNB1 (Cyclin B1) • CDK3 (Cyclin Dependent Kinase 3) • CEP55 (Centrosomal Protein 55) • CKS2 (CDC28 Protein Kinase Regulatory Subunit 2) • CRYAB (Crystallin Alpha B) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MMP3 (Matrix metallopeptidase 3) • TPM2 (Tropomyosin 2) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    28d
    Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients (PubMed, Arkh Patol)
    Comparative mRNA expression analysis confirms that a short preoperative course of aromatase inhibitors induces a more potent and uniform molecular response, characterized by profound suppression of proliferation and complete inhibition of estrogen-dependent signaling. Tamoxifen therapy is also effective but results in less pronounced suppression of key targets and, crucially, may be accompanied by early activation of the MYC oncogene, a potential marker for resistance development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FGFR4 (Fibroblast growth factor receptor 4) • BIRC5 (Baculoviral IAP repeat containing 5) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • FOXA1 (Forkhead Box A1) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • BAG1 (BAG Cochaperone 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYBL2 (MYB Proto-Oncogene Like 2) • SFRP1 (Secreted frizzled related protein 1) • TMEM45B (Transmembrane Protein 45B) • ANLN (Anillin Actin Binding Protein) • CCNB1 (Cyclin B1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 negative • HER-2 expression
    |
    tamoxifen • letrozole • anastrozole
    1m
    Are PTTG1 variants associated with tumor characteristics and p53/Ki-67 expression in pituitary neuroendocrine tumors. (PubMed, Front Endocrinol (Lausanne))
    We can hypothesize that the variant may alter gene expression or protein function, thereby predisposing to PitNETs development at an earlier stage (microadenomas). Future research should integrate molecular studies with larger genetic datasets to clarify how PTTG1 variants contribute to PitNETs' pathophysiology.
    Journal
    |
    TP53 (Tumor protein P53) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin)
    1m
    Tumor prognostic risk stratification based on pseudo-time analysis of single-cell sequencing for patients with lung adenocarcinoma. (PubMed, J Thorac Dis)
    In addition, multi-center datasets and immunohistochemistry revealed a significant up-regulation of DDIT4, FURIN, PTTG1 and RIPK2 at transcriptional and protein expression levels in LUAD tissues compared to normal tissues. PTDGs are potential biological markers for prognostic risk stratification of patients with LUAD.
    Journal
    |
    PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • RIPK2 (Receptor Interacting Serine/Threonine Kinase 2) • DDIT4 (DNA Damage Inducible Transcript 4)
    2ms
    Identification and Validation of the Prognostic Value of PTTG1-Related Genes in Hepatocellular Carcinoma by Mendelian Randomization and Single-Cell Transcriptome Analysis. (PubMed, Iran J Biotechnol)
    Cell communication analysis showed enhanced interactions between PTTG1-highly expressed cells and fibroblasts, myeloid cells, and endothelial cells; experimental validation confirmed elevated expression of CDC45 and CENPE in the HCC group in addition to PTTG1. Overall, CDC45 and CENPE, as prognostic genes related to PTTG1, provided new research perspectives and potential therapeutic targets for HCC treatment.
    Journal
    |
    PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC45 (Cell Division Cycle 45)
    2ms
    UBE2C/PTTG1 Regulates PANoptosis, Ferroptosis, and Autophagy to Improve Renal Ischemia-Reperfusion Injury. (PubMed, FASEB J)
    The effect of UBE2C may be reversed by intervention on PTTG1 expression, and UBE2C regulated PTTG1 expression by affecting its ubiquitination. Our results suggested that UBE2C might promote PTTG1 expression by enhancing its stability through decreasing ubiquitination to inhibit Panopolis and ferroptosis while facilitating autophagy to protect the kidney from IR-induced AKI.
    Journal
    |
    PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    2ms
    Novel common target genes for breast cancer and colorectal cancer: a Mendelian randomization and spatial transcriptomics study. (PubMed, Discov Oncol)
    This study reports that the ZFP36L2, CKS1B, PTTG1, and ITGAE genes could potentially influence breast cancer and colorectal cancer development via TCM CD8 + T cells. These four genes are putative common markers for diagnosis, treatment, and monitoring tumor response to therapies.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ITGAE (Integrin Subunit Alpha E) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • ZFP36 (ZFP36 Ring Finger Protein)
    2ms
    A novel prognostic model in ovarian cancer based on the Nectin family and Necl-like molecules related transcriptomics. (PubMed, SLAS Technol)
    We identified six prognosis-related genes and constructed a prognostic model, providing a theoretical basis for the clinical prognosis prediction and treatment for OC patients.
    Journal
    |
    CD8 (cluster of differentiation 8) • TOP2A (DNA topoisomerase 2-alpha) • CD4 (CD4 Molecule) • PLK1 (Polo Like Kinase 1) • TGFB1 (Transforming Growth Factor Beta 1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • KIF20A (Kinesin Family Member 20A)
    3ms
    Construction and validation of an oxidative phosphorylation-related gene signature in lung squamous cell carcinoma patients. (PubMed, Lung Cancer Manag)
    This signature highlights the clinical relevance of OXPHOS in LUSC prognosis and may guide personalized therapeutic strategies targeting metabolic vulnerabilities. Study limitations include its retrospective design and lack of experimental validation.
    Journal • Gene Signature
    |
    SAA1 (Serum Amyloid A1) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC25C (Cell Division Cycle 25C) • SAAL1 (Serum Amyloid A Like 1) • CD59 (CD59 Molecule) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    3ms
    Emerging Roles of PTTG1/Securin in Breast Cancer. (PubMed, J Cancer)
    Lastly, we explore how securin influences the malignant behaviors of BC cells. This review emphasizes the critical connection between CIN and BC pathobiology mediated by securin and offers insights for future research into securin-related mechanisms and therapeutic strategies.
    Review • Journal
    |
    PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin)